Ginkgo reports Q1 2026 revenue down 49% post-Biosecurity divestiture, focusing on autonomous labs growth.

Ginkgo Bioworks announced a 49% revenue decline to $19 million in Q1 2026 following the divestiture of its Biosecurity business, with a GAAP net loss of $76 million. The company is pivoting towards expanding its autonomous lab platform, Nebula, aiming to double its size in 2026 to lead the transition from manual lab work to automated research integrated with AI. Despite lower revenue, Ginkgo maintains a strong cash position of $373 million and expects a cash burn of $125-150 million for the full year 2026. The focus remains on scaling autonomous labs and strategic partnerships to drive future growth.